The purpose of this study is to establish safety and feasibility of utilizing Adipose-Derived Stem and Regenerative Cells (ADRC's) in patients who have suffered a ST-elevation acute myocardial infarction.

Subjects who have coronary artery disease and have suffered a ST-elevation acute myocardial infarction will be evaluated for eligibility in this study. Eligible subjects will undergo standard treatment after admission to the hospital and will then undergo liposuction under local anesthesia, after which ADRC's will be isolated from the lipoaspirate. According to randomization subjects will receive either ADRC's or placebo.

Key Inclusion Criteria:

• Acute myocardial infarction (AMI)
• Clinical symptoms consistent with AMI for a minimum of 2 and a maximum of 12 hours from onset of symptoms to Percutaneous Coronary Intervention (PCI), and unresponsive to nitroglycerin
• Successful revascularization of the culprit lesion in the major epicardial vessel
• Area of hypo- or akinesia corresponding to the culprit lesion, as determined by left ventriculogram at the time of primary PCI
• Left ventricular ejection fraction (LVEF) ≥30% and ≤50% by Left Ventricular Angiography at the time of successful revascularization.
• Ability to undergo liposuction

Key Exclusion Criteria:

• Prior MI, prior known cardiomyopathy, or prior hospital admission for congestive heart failure (CHF)
• More than 24 hours after acute PCI
• Significant valvular disease
• More than twelve hours between the onset of first symptoms of AMI and revascularization
• Hemodynamic instability within 24 hours prior to randomization
• Neoplasia
• Acute or chronic bacterial or viral infectious disease
• Pacemaker, ICD or any other contra-indication for MRI
• LVEF <30% or >50% by Left Ventricular Angiography
• Moderate or severe COPD